ASCO permits users, at no charge, to download and make presentation slides of this material for personal and educational use, including noncommercial instruction and presentation at noncommercial conferences. Appropriate attribution to JCO is required. All other uses, including print distribution, require prior permission from ASCO.
(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.
Fig 1. (A) Scatter graph of the incidence of rash at different ABX-EGF doses (•), with the line representing the percentage of rash predicted using a sigmoidal Emax model. This model predicted that 90% of patients would develop rash at 1.5 ± 0.26 mg/kg/wk (95%CI, 1.0 to 2.0 mg/kg/wk). (B) The percentages of subjects with a particular grade of rash at different doses.
|
